Physician profile
Wayne Ormsby
NPI 1851417158
$1,044.09
in general payments reported to CMS, 2019-2025
17 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2021: $32.90 · 2022: $67.48 · 2023: $117 · 2024: $194 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.76 |
| Education | $128.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $149.20 | 2025 | Yescarta |
| Janssen Biotech, INC. | $105.34 | 2019-2023 | Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $103.18 | 2022-2025 | Enhertu |
| Pfizer INC. | $96.83 | 2019-2025 | |
| Genmab U.S., INC. | $95.66 | 2024-2025 | Tivdak, Epkinly |
| Genentech USA, INC. | $76.89 | 2019-2024 | Lunsumio |
| Aveo Pharmaceuticals, INC. | $69.99 | 2023 | Fotivda |
| Genzyme Corporation | $60.63 | 2025 | |
| Lilly USA, LLC | $58.54 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $50.75 | 2025 | Imfinzi |
| Amgen INC. | $43.79 | 2019-2025 | |
| Taiho Oncology, INC. | $43.30 | 2019 | |
| Abbvie INC. | $31.73 | 2025 | |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Incyte Corporation | $20.62 | 2025 | Jakafi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,586.19 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Ormsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.